ID   HCC827 GR2
AC   CVCL_V621
DR   cancercelllines; CVCL_V621
DR   GEO; GSM466321
DR   Progenetix; CVCL_V621
DR   Wikidata; Q54881789
RX   PubMed=17463250;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 15
//
RX   PubMed=17463250; DOI=10.1126/science.1141478;
RA   Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C.,
RA   Park J.O., Lindeman N.I., Gale C.-M., Zhao X.-J., Christensen J.G.,
RA   Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C.,
RA   Johnson B.E., Cantley L.C., Janne P.A.;
RT   "MET amplification leads to gefitinib resistance in lung cancer by
RT   activating ERBB3 signaling.";
RL   Science 316:1039-1043(2007).
//